Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Colorectal Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasms 6Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Glioblastoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Diseases 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

pembrolizumab 24Paclitaxel 20Carboplatin 19Taxes 7temsirolimus 6Trastuzumab 6Topotecan 5Radiotherapy 5Cisplatin 5atezolizumab 4Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Gemcitabine 4Docetaxel 4Biopsy 4Bevacizumab 4olaparib 3lenvatinib 3dostarlimab 3Sirolimus 3Pemetrexed 3Irinotecan 3Interleukin-12 Subunit p35 3Fulvestrant 3Cetuximab 3Albumin-Bound Paclitaxel 3spartalizumab 2gedatolisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Neoplasms × spartalizumab × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04152018 2025-05-28

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Pfizer

Phase 1 Terminated
85 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡